Infant Bacterial Therapeutics AB (publ) Asset Resilience Ratio

Latest as of March 2025: 92.23%

Infant Bacterial Therapeutics AB (publ) asset resilience ratio. Infant Bacterial Therapeutics AB (publ) (IBT-B) has an Asset Resilience Ratio of 92.23% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IBT-B cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

Skr191.76 Million

≈ $20.64 Million USD Cash + Short-term Investments

Total Assets

Skr207.92 Million

≈ $22.38 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio of Infant Bacterial Therapeutics AB (publ) (2016–2024)

Asset resilience ratio of Infant Bacterial Therapeutics AB (publ) from 2016 to 2024. This chart shows how Infant Bacterial Therapeutics AB (publ)'s Asset Resilience Ratio has changed over time. Read Infant Bacterial Therapeutics AB (publ) (IBT-B) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Infant Bacterial Therapeutics AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see IBT-B asset base.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr191.76 Million	92.23%
Short-term Investments	Skr0.00	0%
Total Liquid Assets	Skr191.76 Million	92.23%

Asset Resilience Insights

Very High Liquidity: Infant Bacterial Therapeutics AB (publ) maintains exceptional liquid asset reserves at 92.23% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Infant Bacterial Therapeutics AB (publ) Industry Peers by Asset Resilience Ratio

Compare Infant Bacterial Therapeutics AB (publ)'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Bavarian Nordic CO:BAVA	Biotechnology	10.83%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Infant Bacterial Therapeutics AB (publ) Asset Resilience Ratio by Year (2016–2024)

Infant Bacterial Therapeutics AB (publ) asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Infant Bacterial Therapeutics AB (publ).

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	93.25%	Skr223.39 Million ≈ $24.04 Million	Skr239.57 Million ≈ $25.78 Million	-0.41pp
2023-12-31	93.66%	Skr329.06 Million ≈ $35.41 Million	Skr351.33 Million ≈ $37.81 Million	-2.40pp
2022-12-31	96.06%	Skr335.84 Million ≈ $36.14 Million	Skr349.62 Million ≈ $37.62 Million	+1.38pp
2021-12-31	94.68%	Skr386.75 Million ≈ $41.62 Million	Skr408.48 Million ≈ $43.96 Million	+0.65pp
2020-12-31	94.03%	Skr423.44 Million ≈ $45.57 Million	Skr450.32 Million ≈ $48.46 Million	-1.51pp
2019-12-31	95.55%	Skr495.19 Million ≈ $53.29 Million	Skr518.27 Million ≈ $55.77 Million	-0.69pp
2018-12-31	96.24%	Skr542.17 Million ≈ $58.35 Million	Skr563.37 Million ≈ $60.63 Million	+5.81pp
2017-12-31	90.43%	Skr158.27 Million ≈ $17.03 Million	Skr175.02 Million ≈ $18.84 Million	+5.25pp
2016-12-31	85.18%	Skr93.79 Million ≈ $10.09 Million	Skr110.11 Million ≈ $11.85 Million	--

pp = percentage points

About Infant Bacterial Therapeutics AB (publ)

ST:IBT-B Sweden Biotechnology

Market Cap

$108.85 Million

Skr1.01 Billion SEK

Market Cap Rank

#18691 Global

#322 in Sweden

Share Price

Skr77.70

Change (1 day)

+3.60%

52-Week Range

Skr43.45 - Skr82.80

All Time High

Skr266.00